Horizon Pharmaceuticals

Global Study Partner

A world-class pharmaceutical partner focused on advancing long-term wellness through large-scale global health studies.

Areas of Expertise

Our partners specialize in rare, autoimmune, and severe inflammatory diseases, developing therapies for complex conditions often overlooked by larger entities.

Credentials & Education

Led by pioneers in immunology and rare disease, Horizon maintains strategic research collaborations with top academic institutions like Johns Hopkins University.

At BC Patient Recruitment, we partner with organizations that prioritize the most vulnerable patient populations. Horizon Pharmaceuticals is a global biotechnology leader dedicated to transforming the lives of people living with rare, autoimmune, and severe inflammatory diseases.

Focusing on the Unmet Need

Horizon’s research strategy targets conditions where conventional treatments are often nonexistent. By focusing on immune-mediated disorders and severe inflammation, they develop therapies for diseases like refractory gout and thyroid eye disease that significantly impair quality of life. Through our ecosystem, patients gain access to these specialized, high-impact clinical trials.

Advancing Safety and Efficacy

Safety is the cornerstone of Horizon’s R&D efforts. Their trials utilize novel endpoints and dosing strategies to optimize patient outcomes while minimizing risks. Every Horizon-sponsored study is overseen by Institutional Review Boards (IRB) and adheres to rigorous global regulatory standards.

A Collaborative Scientific Network

Participants in a Horizon trial are supported by an expert team of Healthcare Providers and Clinical Research Coordinators. By integrating advanced molecular approaches like siRNA technology, Horizon continues to push the boundaries of what is possible in specialized medicine.

By joining a Horizon-sponsored study, you are contributing to a legacy of "fierce determination" aimed at making a measurable difference for underserved medical communities.